Company intelligence / Profile preview

DV8

San Francisco, California, USA

Ownership: Private
Development stage: Other

Overview

DV8 is a San Francisco-based biotechnology company focused on developing a next-generation platform for the precision delivery of genetic medicines. Co-founded by UC Berkeley professors David Schaffer and Sanjay Kumar, the company aims to overcome the primary biological barriers that limit the effectiveness of current gene and RNA therapies. By engineering advanced delivery vehicles, DV8 seeks to enable tissue-specific targeting and improve the safety and efficacy of genetic payloads. The company is led by CEO Jeff Jonker and is supported by a syndicate of top-tier investors, including GV, F-Prime Capital, and Lux Capital.

Therapeutic areas: OncologyNeurologyRare Diseases
Modalities: Gene therapyRNA therapyLipid nanoparticle delivery therapy
Industry: Biotech

Beyond the preview

Go deeper on DV8.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DV8.

Explore the full profile